期刊文献+

Synthesis and Characterization of Pyrazoleanthrone Derivatives as Aurora A Kinase Inhibitors

Synthesis and Characterization of Pyrazoleanthrone Derivatives as Aurora A Kinase Inhibitors
原文传递
导出
摘要 Aurora A is a cell cycle kinase linked to cancer. For the purpose of finding biologically active of novel compounds and providing new ideas for drug-design, we performed virtual screening in commercially available databases and got pyrazoleanthrone with promising inhibitory activity against Aurora A. Optimization of solvent accessible C7 position of pyrazoleanthrone made us get thirteen target compounds. These pyrazoleanthrone derivatives were evaluated by Aurora A inhibition assays in vitro. The results show that some target compounds could inhibit Aurora A kinase. Meanwhile, these title compounds were tested in vitro against hepatocellular carcinoma(HepG2) cells by the 3'-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT) method, showing that most of them had inhibitory potency. The inhibition rate of compound 6h was about 80% against HepG2 cells, and the 1C50 value was 17.4 μmol/L, which would be considered for further study. Aurora A is a cell cycle kinase linked to cancer. For the purpose of finding biologically active of novel compounds and providing new ideas for drug-design, we performed virtual screening in commercially available databases and got pyrazoleanthrone with promising inhibitory activity against Aurora A. Optimization of solvent accessible C7 position of pyrazoleanthrone made us get thirteen target compounds. These pyrazoleanthrone derivatives were evaluated by Aurora A inhibition assays in vitro. The results show that some target compounds could inhibit Aurora A kinase. Meanwhile, these title compounds were tested in vitro against hepatocellular carcinoma(HepG2) cells by the 3'-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT) method, showing that most of them had inhibitory potency. The inhibition rate of compound 6h was about 80% against HepG2 cells, and the 1C50 value was 17.4 μmol/L, which would be considered for further study.
出处 《Chemical Research in Chinese Universities》 SCIE CAS CSCD 2013年第6期1098-1103,共6页 高等学校化学研究(英文版)
关键词 Pyrazoleanthrone Aurora-A kinase INHIBITOR Biological activity Pyrazoleanthrone Aurora-A kinase Inhibitor Biological activity
  • 相关文献

参考文献17

  • 1Glover D.M.,Leibowitz M.H.,McLean D.A.,Parry H.,Cell,1995,81,95.
  • 2Andrews P.D.,Knatko E.,Moore W.J.,Swedlow J.R.,Curr.Opin.Cell Biol.,2003,15,672.
  • 3Andrews P.D.,Oncogene,2005,25,5005.
  • 4Qi W.Q.,Liu X.B.,Cooke L.S.,Persky D.O.,Miller T.P.,Squires M.,Mahadevan D.,Int.J.Cancer,2012,130,299.
  • 5Marumoto T.,Zhang D.,Saya H.,Nat.Rev.Cancer,2005,5,42.
  • 6Kollareddy M.,Zheleva D.,Dzubak P.,Brahmkshatriya P.S.,Lepsik M.,Hajduch M.,Invest.New Drugs,2012,30,2411.
  • 7Fujii S.,Dotto G.P.,Methods and Compositions for Reducing Skin Damage,WO 2007016419 A2,2007-2-8.
  • 8Howard S.,Berdini V.,Boulstridge J.A,Canr M.G.,Cross D.M.,Curry J.,Devine L.A.,Early T.R.,Fazal L.,Gill A.L.,Heathcote M.,Maman S.,Matthews J.E.,McMenamin R.L.,Navarro E.E,O'Brien M.A.,O'Reilly M.,Rees D.C.,Reule M.,Tisi D.,Williams G.,Vinkovit M.,Wyatt P.G.,J.Med.Chem.,2009,52,379.
  • 9Aliagas-Martin I.,Burdick D.,Corson L.,Dotson J.,Drummond J.,Fields C.,Huang O.W.,Hunsaker T.,Kleinheinz T.,Krueger E.,Liang J.,Moffat J.,Phillips G.,Pulk R.,Rawson T.E.,Ultsch M.,Walker L,Wiesmarn C.,Zhang B.,Zhu B.Y.,Cochran A.G.,J.Med.Chem.,2009,52,3300.
  • 10Zhao B.,Smallwood A.,Yang J.,Koretke K.,Nurse K.,Calamari A.,Kirkpatrick R.B.,Lai Z.,Protein Sci.,2008,17,1791.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部